Eniola's strongest angle is to position herself as the rare VSD applicant who arrives having already executed DSV's Year-1 and Year-2 cycles independently: three sole-authored CCT preprints constitute her scoping and hypothesis formation; ODE/RK45 + Bayesian MCMC validation (85.8% encoding-probability reduction, all five pre-registered hypotheses confirmed, super-additivity +12.8 pp) is her invention phase; and IMPRINT, TOPOLOGIX, and GATE are embryonic Year-3 ventures — she is already building the commercialisation layer. Endorsements from Berridge, Gershman, Daw, and Mattar map directly onto the high-calibre supervisor network the programme prizes, and her Nigerian/Lagos independent-researcher identity is the precise non-traditional, LMIC-origin, under-represented profile DSV states it explicitly wants to attract. The proposal should frame VSD not as a place to discover a problem, but as the institutional scaffolding (PhD credential via Woolf, lab network, 400+ investor access) that will allow an already-validated research arc to reach clinical and commercial scale within a Pharma-sector venture.